Subventions financées

This project is a Phase II study involving 100 participants across 8 ALS clinics across Canada. The trial, led by the Principal Investigator of the Canadian Neuromuscular Disease Registry (CNDR) and the Chair of the Canadian ALS Research Network (CALS) will examine whether pimozide, a drug already approved by Health Canada for use in psychoses like schizophrenia and Tourette’s syndrome, might slow progression of ALS.

In Alzheimer’s disease (AD), the accumulation of toxic Tau protein in neurons leads to the formation of neurofbillary tangles, cell death, and cognitive impairments.

Mitochondrial dysfunctions are observed before and during the progression of Alzheimer’s disease (AD).

New neuroimaging techniques enable us to measure the key hallmarks of Alzheimer’s disease (AD) pathology before symptoms appear.

Mr. Little’s current focus is on building computer software that can identify altered brain development patterns in fetal alcohol spectrum disorder (FASD) using brain images.

Parkinson’s Disease (PD) and Amyotrophic Lateral Sclerosis (ALS) are two of the most common and devastating neurodegenerative diseases, affecting more than 2% of the population over the age of 65.

Brain disorders such as autism, major depressive disorder and Alzheimer’s disease are among the greatest medical challenges of our era.

New approaches in neurodevelopmental research increasingly seek to integrate enormous amounts of data through sophisticated informatics so as to determine the relationship between genotype and phenotypes, both structural and functional, as they change over time during development.

More than 1 in 100 individuals are diagnosed with Autism Spectrum Disorder (ASD), with profound impacts on the quality of life of those who are affected and their families.

Alzheimer’s Disease (AD) is a severe dementia that is likely a result of years of buildup in the brain of molecules called amyloid-beta oligomers (AβOs).